Discovery and characterization of potent and selective 4-oxo-4-(5-(5- phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P 1 agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 19, 2011, Pages 6013-6018

  Buzard, Daniel ^a   Han, Sangdon ^a   Thoresen, Lars ^a   Moody, Jeanne ^a,b   Lopez, Luis ^a   Kawasaki, Andrew ^a,c   Schrader, Thomas ^a   Sage, Carleton ^a   Gao, Yinghong ^a,d   Edwards, Jeff ^a,e   Barden, Jeremy ^a   Thatte, Jayant ^a,f   Fu, Lixia ^a,g   Solomon, Michelle ^a   Liu, Ling ^a,h   Al Shamma, Hussien ^a   Gatlin, Joel ^a   Le, Minh ^a   Xing, Charles ^a   Espinola, Sheryll ^a,i   Jones, Robert M ^a   more..

^a ARENA PHARMACEUTICALS   (United States)

^b REGULUS THERAPEUTICS   (United States)

^c Focus Synthesis   (United States)

^d EMD Millipore   (United States)

^e AMYLIN PHARMACEUTICALS INC   (United States)

^f M S 02 422   (United States)

^g Synthetic Genomics Inc   (United States)

^h PFIZER INC   (United States)

ⁱ GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

FTY720; Immunomodulators; S1P 1 agonist; Sphingosine 1 phosphate receptor

Indexed keywords

4 OXO 4 [5 (5 PHENYL 1,2,4 OXADIAZOL 3 YL)INDOLIN 1 YL]BUTANOIC ACID; FINGOLIMOD; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IMMUNOMODULATION; LIVER MICROSOME; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; AUTOIMMUNE DISEASES; BUTYRIC ACIDS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HAPLORHINI; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; NERVE TISSUE PROTEINS; OXADIAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RNA-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 80052560408     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.05.110     Document Type: Article

References (11)

1. V. Brinkmann Br. J. Pharmacol. 158 2009 1173 1182
2. H. Chi Trends Pharmacol. Sci. 32 2011 16
3. N. Cooke, and F. Zecri An. Rep. Med. Chem. 42 2007 245
4. < http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf >.
5. M. Matsuura, T. Imayoshi, K. Chiba, and T. Okumoto Inflamm. Res. 49 2000 404
6. H. Kitabayashi, M. Isobe, N. Watanabe, J. Suzuki, Y. Yazaki, and M.J. Sekiguchi Cardiovasc. Pharmacol. 35 2000 410
7. C. Daniel, N. Sartory, N. Zahn, G. Geisslinger, H. Radeke, and J.J. Stein Immunology 178 2007 2458
8. D. Buzard, T. Jayant, M. Lerner, J. Edwards, and R. Jones Exp. Opin. Ther. Pat. 18 2008 1141
9. T.S. McClintock, and M.R. Lerner Brain Res. Prot. 2 1997 59
10. T. Pham, J. Fells, D. Osborne, E. North, M. Naor, and A.J. Parrill Mol. Graphics Modell. 26 2008 1189
11. M.G. Sanna, J. Liao, E. Jo, C. Alfonso, M. Ahn, M.S. Peterson, B. Webb, S. Lefebvre, J. Chun, N. Gray, and H.J. Rosen Biol. Chem. 14 2004 13839